Clostridium difficile - Associated diarrhea, an emerging epidemic: Therapeutic options

Journal of Pharmacy Practice

Volumn 20, Issue 4, 2007, Pages 347-353

  Emerson, Christopher R ^a  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Antibacterial agents; Clostridium difficile; Colitis; Diarrhea; Recurrence

Indexed keywords

ANTIBIOTIC AGENT; BACITRACIN; COLESTYRAMINE; FUSIDIC ACID; GATIFLOXACIN; IMMUNOGLOBULIN; MEDAREX; METRONIDAZOLE; NITAZOXANIDE; PROBIOTIC AGENT; RAMOPLANIN; RIFALAZIL; TEICOPLANIN; TIACUMICIN B; TOLEVAMER; UNCLASSIFIED DRUG; VANCOMYCIN;

CLINICAL TRIAL; CRYPTOSPORIDIOSIS; DISEASE SEVERITY; EPIDEMIC; GIARDIASIS; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INFECTIOUS DIARRHEA; RECURRENT DISEASE; REVIEW; RISK FACTOR; TREATMENT FAILURE;

EID: 36249020351     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190007302892     Document Type: Review

References (43)

1. Bartlett JG New drugs for Clostridium difficile infection. Clin Infect Dis. 2006 ; 43: 428-431.
2. Center for Disease Control and Prevention. Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005. MMWR Morb Mortal Wkly Rep. 2005 ; 54: 1201-1205.
3. Maroo S., LaMont JT Recurrent Clostridium difficile. Gastroenterology. 2006 ; 130: 1311-1316.
4. Aslam S., Hamill RJ, Musher DM Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis. 2005 ; 5: 549-557.
5. Surowiec D., Kuyumjian AG, Wynd MA, Cicogna CE Past, present, and future therapies for Clostridium difficile-associated disease. Ann Pharmacother. 2006 ; 40: 2155-63.
6. Kelly CP, Pothoulakis C., LaMont JT Clostridium difficile colitis. N Engl J Med. 1994 ; 330: 257-262.
7. Pépin J., Valiquette L., Alary M., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004 ; 171: 466-472.
8. Bouza E., Burillo A., Muñoz P. Antimicrobial therapy of Clostridium difficile-associated diarrhea. Med Clin N Am. 2006 ; 90: 1141-1163.
9. Bartlett JG, Perl TM The new Clostridium difficile-What does it mean? N Engl J Med. 2005 ; 353: 2503-2505.
10. McDonald LC, Killgore GE, Thompson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005 ; 353: 2433-2441.
11. Loo VG, Poirier L., Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005 ; 353: 2442-2449.
12. Jodlowski TZ, Oehler R., Kam LW, Melnychuk I. Emerging therapies in the treatment of Clostridium difficile-associated disease. Ann Pharmacother. 2006 ; 40: 2164-2169.
13. Cloud J., Kelly CP Update on Clostridium difficile associated disease. Curr Opin Gastroenterol. 2007 ; 23: 4-9.
14. Kyne L., Hamel B., Polavaram R., Kelly CP Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002 ; 34: 346-353.
15. Bartlett JG Antibiotic-associated diarrhea. N Engl J Med. 2002 ; 346: 334-339.
16. McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis. 2005 ; 40: 265-272.
17. Pépin J., Saheb N., Coulombe M., et al. Emergence of fluroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005 ; 41: 1254-1260.
18. Dial S., Alrasadi K., Manoukian C., Huang A., Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004 ; 171: 33-38.
19. Dial S., Delaney JAC, Schneider V., Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ. 2006 ; 175: 745-748.
20. Lowe DO, Mamdani MM, Kopp A., Low DE, Juurlink DN Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis. 2006 ; 43: 1272-1276.
21. Poutanen SM, Simor AE Clostridium difficile-associated diarrhea in adults. CMAJ. 2004 ; 171: 51-58.
22. Gerding DN, Johnson S., Peterson LR, Mulligan ME, Silva J. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995 ; 16: 459-477.
23. Guerrant RL, Van Gilder T., Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis. 2001 ; 32: 331-350.
24. Center for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance recommendations of the hospital infection control practices advisory committee (HICPAC). MMWR Morb Mortal Wkly Rep. 1995 ; 44 (RR12). 1-13.
25. Vancocin [package insert]. Exton, PA: ViroPharma Incorporated ; 2005.
26. Gerding DN Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clin Infect Dis. 1997 ; 25 (Suppl 2). S206-210.
27. Fernandez A., Anand G., Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J Clin Gastroenterol. 2004 ; 38: 414-418.
28. Musher DM, Aslam S., Logan N., et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005 ; 40: 1586-1590.
29. Pépin J., Alary M., Valiquette L., et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005 ; 40: 1591-1597.
30. Musher DM, Logan N., Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis. 2006 ; 43: 421-427.
31. Dudley MN, McLaughlin JC, Carrington G., Frick J., Nightingale CH, Quintiliani R. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. Arch Intern Med. 1986 ; 146: 1101-1104.
32. Young GP, Ward PB, Bayley N., et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology. 1985 ; 89: 1038-1045.
33. Kyne L., Warny M., Qmar A., Kelly CP Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. New Engl J Med. 2000 ; 342: 390-397.
34. Kyne L., Warny M., Qmar A., Kelly CP Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001 ; 357: 189-193.
35. McPherson S., Rees CJ, Ellis R., Soo S., Panter SJ Intravenous immunoglobulin for the treatment of severe refractory and recurrent Clostridium difficile diarrhea. Dis Colon Rectum. 2006 ; 49: 640-645.
36. Wilcox MH Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother. 2004 ; 53: 882-884.
37. Beales IL Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea [letter]. Gut. 2002 ; 51: 456.
38. Apisarnthanarak A., Razavi B., Mundy LM Adjunctive intra-colonic vancomycin for severe Clostridium difficile colitis: case series and review of literature. Clin Infect Dis. 2002 ; 35: 690-696.
39. Wenisch C., Parschalk B., Hasenhündl M., Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis. 1996 ; 22: 813-818.
40. Dendukuri N., Costa V., McGregor M., Brophy JM Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ. 2005 ; 173: 167-170.
41. Aas J., Gessert CE, Bakken JS Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003 ; 36: 580-585.
42. Louie TJ, Peppe J., Watt CK, et al. Tolevamer, a novel antibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis. 2006 ; 43: 411-420.
43. Pullman J., Prieto J., Leach TS Ramoplanin vs. vancomycin in the treatment of Clostridium difficile diarrhea: a phase 2 study (abstracts). Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004 ; Washington, DC.